0
August 17, 1984, Vol 252, No. 7 >
ARTICLE | August 17, 1984

Neuropsychiatric Manifestations of Human Leukocyte Interferon Therapy in Patients With Cancer FREE

Frank Adams, MD, FRCP(C); Jorge R. Quesada, MD; Jordan U. Gutterman, MD
[+] Author Affiliations

Reprint requests to Section of Neuropsychiatry, The University of Texas M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave, Houston, TX 77030 (Dr Adams).


JAMA. 1984;252(7):938-941. doi:10.1001/jama.1984.03350070056026
Text Size: A A A
Published online
Article
References

The conditions of ten patients with metastatic renal cell carcinoma were serially evaluated by neuropsychiatric examination to determine the nature of the fatigue-asthenia symptoms resulting from human leukocyte interferon alpha therapy. The majority of the patients had moderate to severe behavioral changes and mild to moderate cognitive, affective, and personality changes within the first week of daily intramuscular administration of 3×106 units of interferon. This descriptive clinical study suggests that the intense fatigue may be a manifestation of a complex neurotoxicity, most suggestive of frontal lobe changes, and resulting in neurasthenia syndrome with reversible impairment of some higher mental functions.

(JAMA 1984;252:938-941)

REFERENCES

1 +
Gutterman J, Blumenschein JR, Alexanian R, et al:  Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma . Ann Intern Med 1980;;83:399-406.
2 +
Quesada JR, Swanson D, Trindade A, et al:  Antitumor effects of partially pure human leukocyte interferon in renal cell carcinoma . Cancer Res 1982;;43:940-947.
3 +
Scott GM, Secher DS, Flowers D:  Toxicity of interferon . Br Med J 1981;;282:1345.
4 +
Cantell K, Hirvonen S:  Large-scale production of human leukocyte interferon containing 10 units per ml . J Gen Virol 1978;;39:541-543.
5 +
Hutt ML: The Hutt Adaptation of the Bender-Gestalt Test , ed 2. New York, Grune & Stratton Inc, 1969;.
6 +
Reitan R:  Validity of the Trail Making Test as an indicator of organic brain damage . Percept Mot Skills 1978;;8:271-276.
7 +
Wechsler D: Wechsler Adult Intelligence Scale Manual . New York, Psychological Corp, 1955;.
8 +
Lishman AL: Organic Psychiatry: The Psychological Consequences of Cerebral Disorder . Oxford, England, Blackwell Scientific Publications, 1978;, pp 109-175.
9 +
Strub RL, Black WF: Organic Brain Syndromes: An Introduction to Neurobehavioral Disorders . Philadelphia, FA Davis Co, 1981;, pp 38-85.
10 +
Smedley H, Katrak M, Sikora K, et al:  Neurological effects of recombinant human interferon . Br Med J 1983;;286:262-264.
11 +
Rohatiner AZS, Prior PF, Burton AC, et al:  Central nervous systemic toxicity of interferon . Br J Cancer 1983;;47:418-422.
12 +
Cantell K, Mattson K, Nirranan A, et al:  Neurotoxicity of IFN . Read before the Third International Congress of Interferon Research, Miami, Nov 1-3, 1982 .
13 +
Damasio A:  The frontal lobes , in Heilman KM, Valenstein E (eds): Clinical Neuropsychology . New York, Oxford University Press, 1979;, pp 360-412.
14 +
Hecaen H, Albert ML:  Disorders of mental functioning related to frontal lobe pathology , in Benson FS, Blumer D (eds): Psychiatric Aspects of Neurological Disease: Seminars in Psychiatry . New York, Grune & Stratton Inc, 1974;, pp 137-149.
15 +
Luria AR:  Frontal lobe syndromes , in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology . New York, Elsevier North Holland Inc, 1969;, vol 2, pp 725-757.
16 +
Fuster JM: The Prefrontal Cortex: Anatomy, Physiology and Neuropsychology of the Frontal Lobe . New York, Raven Press, 1978;, pp111-124.
17 +
Luria AR: Higher Cortical Functions in Man , ed 2. New York, Basic Books Inc, 1980;, pp 246-359.
18 +
Gutterman JU, Fine S, Quesada J, et al:  Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients . Ann Intern Med 1982;;96:549-556.
19 +
Calvet MC, Gresser I:  Interferon enhances the excitability of cultures neurons . Nature 1979;;178:558-560.
20 +
Maheshware RK, Lazo PS, Friedman RM:  Enhancement of interferon activity by a membrane glycoprotein related to the thyrotropin receptor , in Khan S, Hill NO, Dorn GL (eds): Interferon: Properties and Clinical Uses . Dallas, Leland Fikes Foundation Press of the Wadley Institute of Molecular Medicine, 1979;, pp 387-396.
21 +
Blalock JE, Smith EM:  Human leukocyte interferon: Potent endorphin-like opioid activity . Biochem Biophys Res Commun 1981;;101:472-478.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Gutterman J, Blumenschein JR, Alexanian R, et al:  Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma . Ann Intern Med 1980;;83:399-406.
2 +
Quesada JR, Swanson D, Trindade A, et al:  Antitumor effects of partially pure human leukocyte interferon in renal cell carcinoma . Cancer Res 1982;;43:940-947.
3 +
Scott GM, Secher DS, Flowers D:  Toxicity of interferon . Br Med J 1981;;282:1345.
4 +
Cantell K, Hirvonen S:  Large-scale production of human leukocyte interferon containing 10 units per ml . J Gen Virol 1978;;39:541-543.
5 +
Hutt ML: The Hutt Adaptation of the Bender-Gestalt Test , ed 2. New York, Grune & Stratton Inc, 1969;.
6 +
Reitan R:  Validity of the Trail Making Test as an indicator of organic brain damage . Percept Mot Skills 1978;;8:271-276.
7 +
Wechsler D: Wechsler Adult Intelligence Scale Manual . New York, Psychological Corp, 1955;.
8 +
Lishman AL: Organic Psychiatry: The Psychological Consequences of Cerebral Disorder . Oxford, England, Blackwell Scientific Publications, 1978;, pp 109-175.
9 +
Strub RL, Black WF: Organic Brain Syndromes: An Introduction to Neurobehavioral Disorders . Philadelphia, FA Davis Co, 1981;, pp 38-85.
10 +
Smedley H, Katrak M, Sikora K, et al:  Neurological effects of recombinant human interferon . Br Med J 1983;;286:262-264.
11 +
Rohatiner AZS, Prior PF, Burton AC, et al:  Central nervous systemic toxicity of interferon . Br J Cancer 1983;;47:418-422.
12 +
Cantell K, Mattson K, Nirranan A, et al:  Neurotoxicity of IFN . Read before the Third International Congress of Interferon Research, Miami, Nov 1-3, 1982 .
13 +
Damasio A:  The frontal lobes , in Heilman KM, Valenstein E (eds): Clinical Neuropsychology . New York, Oxford University Press, 1979;, pp 360-412.
14 +
Hecaen H, Albert ML:  Disorders of mental functioning related to frontal lobe pathology , in Benson FS, Blumer D (eds): Psychiatric Aspects of Neurological Disease: Seminars in Psychiatry . New York, Grune & Stratton Inc, 1974;, pp 137-149.
15 +
Luria AR:  Frontal lobe syndromes , in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology . New York, Elsevier North Holland Inc, 1969;, vol 2, pp 725-757.
16 +
Fuster JM: The Prefrontal Cortex: Anatomy, Physiology and Neuropsychology of the Frontal Lobe . New York, Raven Press, 1978;, pp111-124.
17 +
Luria AR: Higher Cortical Functions in Man , ed 2. New York, Basic Books Inc, 1980;, pp 246-359.
18 +
Gutterman JU, Fine S, Quesada J, et al:  Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients . Ann Intern Med 1982;;96:549-556.
19 +
Calvet MC, Gresser I:  Interferon enhances the excitability of cultures neurons . Nature 1979;;178:558-560.
20 +
Maheshware RK, Lazo PS, Friedman RM:  Enhancement of interferon activity by a membrane glycoprotein related to the thyrotropin receptor , in Khan S, Hill NO, Dorn GL (eds): Interferon: Properties and Clinical Uses . Dallas, Leland Fikes Foundation Press of the Wadley Institute of Molecular Medicine, 1979;, pp 387-396.
21 +
Blalock JE, Smith EM:  Human leukocyte interferon: Potent endorphin-like opioid activity . Biochem Biophys Res Commun 1981;;101:472-478.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems